Alcidion Group Limited · ASX:ALC
Alcidion — Investor Presentation (August 2022)
13 slides from Alcidion's investor presentation, Aug 30, 2022
Slide 1: Webinar Presentation: FY22 Full Year Results
Webinar Presentation FY22 Full Year Results 30 August 2022 1
Slide 2: Alcidion – a Snapshot
Alcidion – a Snapshot Alcidion Operates in 2 Geographies • Alcidion‘s purpose is to transform healthcare with (% FY22 Revenue) smart, intuitive technology solutions that improve the efficiency & quality of patient care in healthcare organisations, worldwide ANZ UK • Focus on providing tools to clini
Slide 3: FY22 Summary
FY22 Summary Commercial in Confidence
Slide 4: FY22 – Financial Highlights
FY22 – Financial Highlights1 Strong performance in key financial metrics and record sold revenue heading into FY23 Revenue $34.4M 33% Recurring Revenue $23.3M 42% Gross Margin 85.8% 2.5pts Sold Revenue for FY23 $28.3M 87% Underlying EBITDA2 $0.9M $0.4M FY22 TCV3 new sales $57.7M 96% Operating Cashfl
Slide 5: Revenue
FY22 - Revenue Half-on- half Revenue revenue by region Recurring / non- % recurring Revenue revenue by region 5
Slide 6: Profit & Loss
Profit & Loss Profit & loss ($000) FY22 FY21 % change Key Comments Recurring revenue 23,274 16,343 42% • Record FY22 revenue of $34.4m, up 33% on FY21 Non-recurring revenue 11,081 9,539 16% Total revenue 34,355 25,882 33% A$M Products Product Imp Services Total Direct costs (4,862) (3,018) 61% Recur
Slide 7: Balance Sheet
Balance Sheet Balance sheet ($000) FY22 FY21 Key Comments Cash & cash equivalents 17,339 25,027 • Strong balance sheet with $17.3M cash and no debt Trade & other receivables 7,251 4,114 Other assets 1,672 1,206 • Unearned revenue of $12.9M (up $5.8M) reflects revenue invoiced in Current assets 26,26
Slide 8: Cash Flow
Cash Flow Cash flow ($000) FY22 FY21 Key Comments Receipts from customers 41,449 32,046 Payments to suppliers & employees (40,275) (30,510) Interest recevied 24 12 • Record $41.4M receipts from customers, a $9.4M (29%) increase on FY21 Finance costs (68) (3) Income tax paid (134) - • Positive operat
Slide 9: FY22 Corporate Summary
FY22 Corporate Summary Executed key operational and corporate strategies which underpin future growth profile • In December 2021, acquired Silverlink PCS, one of last few remaining PAS1 providers servicing UK NHS Silverlink • 12 long-standing NHS Trusts (11 new for Alcidion) with 95% recurring reven
Slide 10: FY22 – New & Renewed Contracts
FY22 – New & Renewed Contracts • Queen’s Hospital Burton: South Tees NHS Hospitals: New three-year contract for ExtraMed’s IPFM, first new contract win following ExtraMed acquisition • Royal Derby Hospital: Three-year contract extension, ExtraMed’s IPFM licence & support • NHS Tayside: Five-year agr
Slide 11: Starting FY23 with a strong contracted revenue base
Starting FY23 with a strong contracted revenue base Key Comments • $28.3M of contracted revenue to be recognised in FY23, 87% higher than at same time last year • Further $2.9M of scheduled renewal, expected to be converted to contracted revenue over FY23 Key Growth Drivers: New Contract Wins New co
Slide 12: Disclaimer
Disclaimer The information contained in this document (“Document”) has been prepared by Alcidion Group Limited ACN 143 142 410 (referred to as “Alcidion” or “Company”). This Document is current as at the date of this Document and should be read in conjunction with other Alcidion periodic and continu
Slide 13: Slide 13